Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an update.
Alligator Bioscience AB announced the preliminary results of its TO 12 warrants exercise, with approximately 71% of the warrants exercised, raising around SEK 51.5 million. This outcome indicates that the company’s top guarantee commitments will be partially executed, leading to a total exercise rate of about 85%, amounting to SEK 61.5 million. The final results will be disclosed in a subsequent release, potentially impacting the company’s financial standing and strategic initiatives.
More about Alligator Bioscience AB
Alligator Bioscience is a clinical-stage biotechnology company specializing in the development of tumor-directed immuno-oncology antibody drugs, particularly targeting the CD40 receptor. This approach aims to enhance the immune response against tumors and has shown promise in treating various types of cancer. The company’s lead candidate, mitazalimab, is advancing towards Phase 3 development following positive results in treating metastatic pancreatic cancer. Alligator Bioscience is listed on Nasdaq Stockholm and is based in Lund, Sweden.
Average Trading Volume: 237,832
Current Market Cap: SEK71M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.